---
layout: default
title: Levodopa
parent: 僅模型預測 (L5)
nav_order: 78
evidence_level: L5
indication_count: 1
---

# Levodopa
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Levodopa: Evaluation Pending – No Predicted Indication Data Available

## One-Sentence Summary

Levodopa (DB01235) is a well-established dopaminergic precursor widely recognized in the management of Parkinson's disease and related movement disorders. However, this Evidence Pack contains no TxGNN prediction output — the `predicted_indications` array is empty — meaning no new indication has been identified for evaluation. A full repurposing assessment cannot be completed until critical data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not specified in current Evidence Pack |
| Predicted New Indication | Not available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 – No actual studies; prediction data absent |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack (Data Gap DG002), and no TxGNN-predicted indications have been returned. Without these two inputs, it is not possible to establish a mechanistic bridge between an original indication and any candidate new indication.

Levodopa is broadly understood to act as a dopamine precursor that crosses the blood–brain barrier, addressing dopaminergic deficits in the central nervous system. This profile has historically attracted interest across multiple neurological and movement disorder contexts. However, any claim of mechanistic applicability to a repurposed indication must be grounded in the specific prediction output and its supporting evidence — neither of which is present here.

Before a repurposing rationale can be constructed, the `predicted_indications` array must be populated from the TxGNN model run, and the MOA data gap must be resolved via DrugBank API query.

---

## Safety Considerations

Please refer to the package insert for safety information.

> Both key warnings (DG001) and contraindications are currently unavailable. DG001 is classified as **Blocking** severity, which prevents entry into the standard safety pre-screening (S1) stage. Remediation requires downloading and parsing the TFDA package insert PDF.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack has two blocking or high-severity data gaps — no predicted indications from TxGNN, no mechanism of action, and no safety warnings — making it impossible to conduct a meaningful repurposing evaluation at this time.

**To proceed, the following is needed:**

- **TxGNN prediction run**: The `predicted_indications` array is empty; the model must be executed and output ingested before any indication-level analysis can begin
- **Mechanism of action (DG002 – High)**: Query DrugBank API for DB01235 to retrieve pharmacological class, targets, and MOA description
- **TFDA package insert safety data (DG001 – Blocking)**: Download and parse the TFDA PDF to extract contraindications, key warnings, and special population restrictions before proceeding to safety screening
- **Drug interaction data**: DDI query returned no results; a secondary source (e.g., DrugBank interactions endpoint) should be queried once MOA is confirmed
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

